Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2021 - 2025)

Kiniksa Pharmaceuticals International's Income from Continuing Operations history spans 5 years, with the latest figure at 71894000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 359.34% year-over-year to 71894000.0; the TTM value through Dec 2025 reached 27088000.0, down 311.48%, while the annual FY2025 figure was 27088000.0, 311.48% down from the prior year.
  • Income from Continuing Operations reached 71894000.0 in Q4 2025 per KNSA's latest filing, down from 18435000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 224093000.0 in Q3 2022 to a low of 96967000.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 7992050.0, with a median of 12481500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 833.67% in 2022, then plummeted 359.34% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 127951000.0 in 2021, then plummeted by 175.78% to 96967000.0 in 2022, then surged by 220.01% to 116370000.0 in 2023, then plummeted by 76.18% to 27722000.0 in 2024, then plummeted by 359.34% to 71894000.0 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Income from Continuing Operations are 71894000.0 (Q4 2025), 18435000.0 (Q3 2025), and 17832000.0 (Q2 2025).